Erste Asset Management GmbH Sells 1,503 Shares of Elevance Health, Inc. $ELV

Erste Asset Management GmbH lessened its holdings in Elevance Health, Inc. (NYSE:ELV) by 30.0% during the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 3,508 shares of the company’s stock after selling 1,503 shares during the period. Erste Asset Management GmbH’s holdings in Elevance Health were worth $1,249,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the business. Vanguard Group Inc. boosted its stake in shares of Elevance Health by 0.6% in the 3rd quarter. Vanguard Group Inc. now owns 22,998,645 shares of the company’s stock worth $7,431,322,000 after buying an additional 141,747 shares during the last quarter. Wellington Management Group LLP boosted its stake in shares of Elevance Health by 4.8% in the 3rd quarter. Wellington Management Group LLP now owns 6,621,297 shares of the company’s stock worth $2,139,473,000 after buying an additional 303,099 shares during the last quarter. Artisan Partners Limited Partnership boosted its stake in shares of Elevance Health by 24.5% in the 3rd quarter. Artisan Partners Limited Partnership now owns 4,576,805 shares of the company’s stock worth $1,478,857,000 after buying an additional 901,626 shares during the last quarter. First Eagle Investment Management LLC boosted its stake in shares of Elevance Health by 0.6% in the 4th quarter. First Eagle Investment Management LLC now owns 4,022,874 shares of the company’s stock worth $1,410,219,000 after buying an additional 24,271 shares during the last quarter. Finally, Norges Bank purchased a new position in shares of Elevance Health in the 4th quarter worth approximately $1,058,165,000. Hedge funds and other institutional investors own 89.24% of the company’s stock.

Elevance Health Trading Down 4.7%

NYSE:ELV opened at $404.33 on Thursday. The company has a current ratio of 1.48, a quick ratio of 1.48 and a debt-to-equity ratio of 0.70. The stock has a market capitalization of $87.81 billion, a PE ratio of 17.20, a price-to-earnings-growth ratio of 2.40 and a beta of 0.67. The firm’s 50 day moving average is $362.40 and its 200 day moving average is $343.89. Elevance Health, Inc. has a 12 month low of $273.71 and a 12 month high of $426.98.

Elevance Health (NYSE:ELV) last posted its quarterly earnings results on Wednesday, April 22nd. The company reported $12.58 EPS for the quarter, topping analysts’ consensus estimates of $10.74 by $1.84. The company had revenue of $49.49 billion for the quarter, compared to analysts’ expectations of $48.21 billion. Elevance Health had a net margin of 2.62% and a return on equity of 15.58%. Elevance Health’s revenue was up 1.5% on a year-over-year basis. During the same quarter in the previous year, the firm posted $11.97 EPS. Elevance Health has set its FY 2026 guidance at 19.850- EPS. Sell-side analysts expect that Elevance Health, Inc. will post 26.94 earnings per share for the current year.

Elevance Health Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, June 25th. Investors of record on Wednesday, June 10th will be issued a $1.72 dividend. This represents a $6.88 dividend on an annualized basis and a dividend yield of 1.7%. The ex-dividend date of this dividend is Wednesday, June 10th. Elevance Health’s payout ratio is 29.26%.

Analysts Set New Price Targets

A number of equities analysts have recently weighed in on ELV shares. Morgan Stanley boosted their target price on Elevance Health from $352.00 to $404.00 and gave the stock an “equal weight” rating in a research note on Thursday, June 4th. Sanford C. Bernstein boosted their target price on Elevance Health from $384.00 to $424.00 and gave the stock an “outperform” rating in a research note on Friday, April 24th. Mizuho boosted their target price on Elevance Health from $435.00 to $465.00 and gave the stock an “outperform” rating in a research note on Monday. Weiss Ratings upgraded Elevance Health from a “hold (c-)” rating to a “hold (c)” rating in a research note on Monday, May 18th. Finally, Bank of America boosted their target price on Elevance Health from $435.00 to $460.00 and gave the stock a “buy” rating in a research note on Thursday, June 4th. Fourteen investment analysts have rated the stock with a Buy rating and nine have issued a Hold rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $416.11.

Elevance Health Company Profile

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.